A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

NCT ID: NCT05036135

Last Updated: 2024-08-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

202 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-02

Study Completion Date

2024-08-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

IMPAHCT: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial is a Phase 2b/Phase 3 study to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in patients with Pulmonary Arterial Hypertension (PAH). The Phase 2b part of the study will assess three doses to establish an optimal dose for the Phase 3 part of the study. The Phase 2b primary endpoint will be the placebo corrected change in pulmonary vascular resistance (PVR). The Phase 3 primary endpoint will be the placebo corrected change in 6-minute walk distance (6MWD) after 24 weeks of treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AV-101 10 mg

Group Type EXPERIMENTAL

AV-101

Intervention Type DRUG

AV-101 (imatinib) administered via dry powder inhalation

AV-101 35 mg

Group Type EXPERIMENTAL

AV-101

Intervention Type DRUG

AV-101 (imatinib) administered via dry powder inhalation

AV-101 70 mg

Group Type EXPERIMENTAL

AV-101

Intervention Type DRUG

AV-101 (imatinib) administered via dry powder inhalation

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo administered via dry powder inhalation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AV-101

AV-101 (imatinib) administered via dry powder inhalation

Intervention Type DRUG

Placebo

Placebo administered via dry powder inhalation

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* PAH belonging to one of the subgroups:

1. I/HPAH, PAH-CTD,
2. PAH due to drugs and/or toxins/chemicals (having been in the care of the investigator for at least one year with no relapses of drug or toxin/chemical abuse),
3. HIV associated or
4. PAH due to repaired congenital heart disease (at least 1 year since repair)
* World Health Organization (WHO) Functional Class II, III or IV symptoms
* Stable concomitant background therapy of at least one PAH approved medications
* Able to walk a distance of at least 100 m but no more than 475 m during the Screening 6-minute walk tests.

Exclusion Criteria

* Pulmonary hypertension (PH) belonging to Groups 2 to 5
* A history of left-sided heart disease
* Pregnant or breast-feeding females

Additional criteria may apply, per protocol
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aerovate Therapeutics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arizona Pulmonary Specialists, Ltd.

Phoenix, Arizona, United States

Site Status

University of Arizona, Department of Medicine

Tucson, Arizona, United States

Site Status

UCLA/David Geffen School of Medicine-Pulmonary and Criticial Care

Los Angeles, California, United States

Site Status

Kaiser Permanente Los Angeles Medical Center

Los Angeles, California, United States

Site Status

Cedars-Sinai Medical Center, Pulmonary & Critical Care

Los Angeles, California, United States

Site Status

Dept of Veterans Affairs Greater Los Angeles Healthcare System

Los Angeles, California, United States

Site Status

UC Davis Medical Center

Sacramento, California, United States

Site Status

University of California

San Francisco, California, United States

Site Status

LA Biomedical Research Institute Harbor

Torrance, California, United States

Site Status

University of Colorado Denver

Aurora, Colorado, United States

Site Status

National Jewish Health

Denver, Colorado, United States

Site Status

George Washington University Medical Faculty Associates, Inc.

Washington D.C., District of Columbia, United States

Site Status

Mayo Clinic Florida

Jacksonville, Florida, United States

Site Status

Orlando Heart Center

Orlando, Florida, United States

Site Status

Emory University

Atlanta, Georgia, United States

Site Status

Indiana University Health

Indianapolis, Indiana, United States

Site Status

University of Iowa Hospitals & Clinics

Iowa City, Iowa, United States

Site Status

University of Kansas Medical Center

Kansas City, Kansas, United States

Site Status

Tufts Medical Center, Inc.

Boston, Massachusetts, United States

Site Status

University of Michigan

Ann Arbor, Michigan, United States

Site Status

University of Minnesota

Minneapolis, Minnesota, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

University of Nebraska Medical Center- Hematology/Oncology Section

Omaha, Nebraska, United States

Site Status

The Unviersity of New Mexico - UNM Hospitals

Albuquerque, New Mexico, United States

Site Status

New York-Presbyterian Brooklyn Methodist Hospital

Brooklyn, New York, United States

Site Status

NYU Langone Seaport

New York, New York, United States

Site Status

Duke University Medical Center - Duke South Clinic

Durham, North Carolina, United States

Site Status

The Lindner Center for Research and Education

Cincinnati, Ohio, United States

Site Status

University of Cincinnati

Cincinnati, Ohio, United States

Site Status

The Ohio State University Wexner Medical Center

Columbus, Ohio, United States

Site Status

Bend Memorial Clinic

Oregon City, Oregon, United States

Site Status

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Site Status

UPMC Presbyterian Hospital

Pittsburgh, Pennsylvania, United States

Site Status

Stat Care Pulmonary Consultants, PLLC

Knoxville, Tennessee, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

Baylor University Medical Center

Dallas, Texas, United States

Site Status

Houston Methodist Hospital

Houston, Texas, United States

Site Status

Sentara Medical Group - Sentara Pulmonary & Critical Care Specialists

Norfolk, Virginia, United States

Site Status

Hospital Britanico de Buenos Aires

Buenos Aires, , Argentina

Site Status

Nexo Salud Investigación Clínica

Buenos Aires, , Argentina

Site Status

Sanatorio de la Trinidad Mitre

Buenos Aires, , Argentina

Site Status

Cardiología Palermo

CABA, , Argentina

Site Status

Insituto Medico DAMIC

Córdoba, , Argentina

Site Status

Hospital Italiano de Cordoba

Córdoba, , Argentina

Site Status

Hospital Dr. Jose Maria Cullen

Santa Fe, , Argentina

Site Status

Royal Prince Alfred Hospital

Camperdown, New South Wales, Australia

Site Status

Concord Repatriation General Hospital

Concord West, New South Wales, Australia

Site Status

Nepean Hospital

Kingswood, New South Wales, Australia

Site Status

Westmead Hospital

Westmead, New South Wales, Australia

Site Status

Sunshine Coast University Hospital

Birtinya, Queensland, Australia

Site Status

The Prince Charles Hospital

Chermside, Queensland, Australia

Site Status

The Alfred Hospital

Melbourne, Victoria, Australia

Site Status

Royal Adelaide Hospital

Adelaide, , Australia

Site Status

Fiona Stanley Hospital

Murdoch, , Australia

Site Status

AKH - Medizinische Universitat Wien

Vienna, , Austria

Site Status

Hopital Erasme - Cliniques Universitaires de Bruxelles

Brussels, , Belgium

Site Status

UZ Leuven

Leuven, , Belgium

Site Status

Santa Casa de Misericordia de Porto Alegre

Porto Alegre, , Brazil

Site Status

Heart Institute - University of Sao Paulo

São Paulo, , Brazil

Site Status

The Governors of the University of Calgary

Calgary, Alberta, Canada

Site Status

University of Alberta Hospital

Edmonton, Alberta, Canada

Site Status

London Health Science Centre

London, Ontario, Canada

Site Status

Jewish General Hospital

Montreal, Quebec, Canada

Site Status

Centro de Investigaciones Clinicas de la Universidad Catolica

Santiago, , Chile

Site Status

Peking Union Medical College Hospital

Beijing, , China

Site Status

Chongqing Medical University - The First Affiliated Hospital

Chongqing, , China

Site Status

Guangdong Provincial People's Hospital

Guangdong, , China

Site Status

Central South University - The Second Xiangya Hospital

Hunan, , China

Site Status

Yanan Hospital of Kunming City

Kunming, , China

Site Status

Gansu Provincial People's Hospital

Lanzhou, , China

Site Status

Southeast University (SEU) - Zhongda Hospital

Nanjing, , China

Site Status

Shanghai Pulmonary Hospital

Shanghai, , China

Site Status

Tianjin Medical University General Hospital

Tianjin, , China

Site Status

Vseobecna fakultni nemocnice v Praze

Prague, , Czechia

Site Status

Groupement Hospitalier Sud - Hôpital Bicêtre

Le Kremlin-Bicêtre, Cedex, France

Site Status

Hôpital Cardio-Vasculaire et Pneumologique Louis Pradel

Bron, , France

Site Status

Hôpital Nord - CHU Marseille

Marseille, , France

Site Status

Hopital Arnaud de Villeneuve

Montpellier, , France

Site Status

Les Hôpitaux Universitaires de Strasbourg

Strasbourg, , France

Site Status

Universitaetsklinikum Carl Gustav Carus TU Dresden

Dresden, , Germany

Site Status

Universitaetsklinikum Giessen und Marburg GmbH Standort Giessen

Giesen, , Germany

Site Status

Universitaetsklinikum Heidelberg

Heidelberg, , Germany

Site Status

München Klinik Bogenhausen

München, , Germany

Site Status

University General Hospital Attikon

Athens, , Greece

Site Status

Cardiosurgery Hospital

Kallithea, , Greece

Site Status

AHEPA General Hospital of Thessaloniki

Thessaloniki, , Greece

Site Status

The Lady Davis Carmel Medical Center

Haifa, , Israel

Site Status

Hadassah University Hospital - Ein Kerem

Jerusalem, , Israel

Site Status

Tel Aviv Sourasky Medical Center

Tel Aviv, , Israel

Site Status

Azienda Ospedaliero Universitaria Ospedali Riuniti - Foggia

Foggia, , Italy

Site Status

Ospedale San Giuseppe - Fatebenefratelli

Milan, , Italy

Site Status

Azienda Socio Sanitaria Territoriale di Monza

Monza, , Italy

Site Status

Azienda Ospedaliera Vincenzo Monaldi

Napoli, , Italy

Site Status

Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione

Palermo, , Italy

Site Status

Fondazione IRCCS Policlinico San Matteo

Pavia, , Italy

Site Status

Azienda Ospedaliera Universitaria Policlinico Umberto I

Rome, , Italy

Site Status

Pauls Stradins Clinical University Hospital

Riga, , Latvia

Site Status

CICUM San Miguel

Guadalajara, Jalisco, Mexico

Site Status

Unidad de Investigacion Clinica en Medicina S.C.

Monterrey, Nuevo León, Mexico

Site Status

Instituto Nacional de Cardiologia Dr Ignacio Chavez Rivera

Mexico City, , Mexico

Site Status

Universidad Autonoma de Nuevo Leon, Hospital Universitario

Monterrey, , Mexico

Site Status

Amsterdam UMC, Locatie VUMC

Amsterdam, , Netherlands

Site Status

Krakowski Szpital Specjalistyczny im. Jana Pawla II

Krakow, , Poland

Site Status

Bieganski Provincial Specialist Hospital

Lodz, , Poland

Site Status

Szpital Kliniczny Przemienienia Pańskiego UM im. Marcinkowskiego

Poznan, , Poland

Site Status

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego

Wroclaw, , Poland

Site Status

Hospital Garcia de Orta, EPE

Almada, , Portugal

Site Status

Hospital Pulido Valente

Lisbon, , Portugal

Site Status

CHUPorto

Porto, , Portugal

Site Status

Cardiopulmonary Research Center

Guaynabo, , Puerto Rico

Site Status

National University Hospital

Singapore, , Singapore

Site Status

Tan Tock Seng Hospital

Singapore, , Singapore

Site Status

Center of Chest Disease Johannesburg

Johannesburg, , South Africa

Site Status

Hospital Universitari Vall d'Hebron

Barcelona, , Spain

Site Status

Hospital Clinic de Barcelona

Barcelona, , Spain

Site Status

Hosp. Universitario Gran Canaria Doctor Negrin

Las Palmas de Gran Canaria, , Spain

Site Status

Hospital 12 de Octubre

Madrid, , Spain

Site Status

Universidad Autonoma de Madrid

Madrid, , Spain

Site Status

Hospital Universitario Virgen de la Victoria

Málaga, , Spain

Site Status

Hospital universtario de Salamanca

Salamanca, , Spain

Site Status

Hosp. Universitario Marques de Valdecilla

Santander, , Spain

Site Status

Hospital Universitario de Toledo

Toledo, , Spain

Site Status

Norrlands Universitetssjukhus

Umeå, , Sweden

Site Status

Imperial College Healthcare NHS Trust

London, England, United Kingdom

Site Status

Golden Jubilee National Hospital

Glasgow, , United Kingdom

Site Status

Royal Brompton Hospital

London, , United Kingdom

Site Status

The Newcastle upon Tyne Hospitals NHS Foundation Trust

Newcastle, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Belgium Brazil Canada Chile China Czechia France Germany Greece Israel Italy Latvia Mexico Netherlands Poland Portugal Puerto Rico Singapore South Africa Spain Sweden United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Gillies H, Chakinala MM, Dake BT, Feldman JP, Hoeper MM, Humbert M, Jing ZC, Langley J, McLaughlin VV, Niven RW, Rosenkranz S, Zhang X, Hill NS. IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension. Pulm Circ. 2024 Mar 25;14(1):e12352. doi: 10.1002/pul2.12352. eCollection 2024 Jan.

Reference Type DERIVED
PMID: 38532768 (View on PubMed)

Gillies H, Niven R, Dake BT, Chakinala MM, Feldman JP, Hill NS, Hoeper MM, Humbert M, McLaughlin VV, Kankam M. AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study. ERJ Open Res. 2023 Mar 13;9(2):00433-2022. doi: 10.1183/23120541.00433-2022. eCollection 2023 Mar.

Reference Type DERIVED
PMID: 36923571 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AV-101-002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.